EHAB Enhabit, Inc. Insider Trading

CFO Ryan buys 10,000 EHAB shares at $7.64; stock now $7.28, -32.6% from 52-week high

Solomon Ryan, CFO of Enhabit, purchased 10,000 shares at $7.64 on 2025-08-08, increasing his holdings to 193,468 shares. The purchase occurred at a price significantly depressed relative to the 52-week range of $6.52–$10.80, with the stock currently trading at $7.28 (-32.6% from the 52-week high). The company faces a challenging backdrop: full-year net income was negative, annual revenue declined 1.1% year-over-year, and the stock has fallen 30.5% over 90 days. While the recent 30-day gain of 3.3% suggests modest recovery, the insider purchase at a reduced valuation point in the context of deteriorating fundamentals warrants attention to whether this reflects executive conviction about stabilization or a routine portfolio adjustment.

Director Bolton Jeffrey purchased 4,000 shares of EHAB at $8.69 on 2024-12-12 (post-transaction holdings: 98.1K shares).

Bolton Jeffrey, a director, purchased 4,000 shares at $8.69 on 2024-12-12, increasing his holdings to 98.1K shares (+4.2% from prior holdings of 94.1K shares). His recent buying activity at this ticker shows mixed results: a purchase on 2024-11-12 gained +12.1% in 30 days, while earlier buys on 2024-11-08 (both) and 2024-08-22 showed near-flat to negative returns, with 0 of 2 measurable same-ticker buys achieving positive 90-day returns. The company remains unprofitable (net income $-110.2M) with declining annual revenue (-2.3% YoY), though the stock has recovered +12.0% over the past 30 days from depressed levels. The transaction occurred at $8.69 versus a current price of $8.52, placing it -26.9% from the 52-week high of $11.65.

Director Stuart M McGuigan purchases 15,000 shares of Enhabit (EHAB) for $132.2K; holdings up 47.2% to 46.8K shares

Director McGuigan acquired 15,000 shares at $8.81 on 2024-12-10, increasing his position by 47.2% to 46.8K total shares worth $132,150. The purchase occurred near the company's 52-week midpoint ($6.89–$11.65 range), at a price 26.8% below the 52-week high. Enhabit reported a net loss of $110.2M on quarterly revenue of $253.6M, with full-year revenue declining 2.3% year-over-year; the company remains unprofitable. The director's accumulation into a loss-making healthcare provider at a depressed valuation point, combined with increasing holdings during operational distress, presents a substantive transaction warranting monitoring of underlying operational trends and the director's conviction thesis.

Director Bolton purchases 10,000 shares over 4 days at $7.72 avg; EHAB unprofitable, stock -34.7% from high

Bolton Jeffrey, Director of EHAB, executed 3 separate purchases totaling 10,000 shares for $77,177.02 between November 8–12, 2024, at a blended average price of $7.72, increasing his holdings by 11.9%. The stock currently trades at $7.61, down -34.7% from its 52-week high of $11.65, though it has recovered 5.7% over the past 30 days. EHAB is unprofitable with a net income of $-110,200,000.00 and negative annual revenue growth of -2.3%, creating a context of fundamental weakness. Bolton's prior EHAB trades show mixed results: his last 4 same-ticker outcomes measurable at the 90-day mark include two wins (May 2024 trades) and two losses (August 2024 trades), with only 50% success rate at that horizon. The current purchase's timing relative to fundamental recovery remains unresolved, and the company's persistent losses warrant scrutiny of the business recovery thesis underlying this accumulation.

Director Bolton Jeffrey purchased 5,000 shares of EHAB at $8.01 on 2024-08-22; stock down 36.6% from 52-week high, but insider has 83.33% win rate on prior buys.

Bolton Jeffrey, a director of Enhabit, Inc., purchased 5,000 shares for $40,050.00 on 2024-08-22, bringing his holdings to 78,877 shares. The transaction occurred as EHAB stock trades at a significant discount to its 52-week high ($8.21 current vs. $12.95 peak, -36.6%), with the company recently reporting an annual revenue decline of -2.3% and a net loss of $-200,000.00 over its most recent full fiscal year. This purchase follows two other open-market buys by the same insider in early August at this ticker, and his cross-ticker track record shows an 83.33% 90-day win rate across 8 prior acquisitions (average 90d return +6.2%). At the same ticker (EHAB), his three prior trades with measurable outcomes were all well-timed at the 90-day mark, including a May 2024 buy followed by a 90d return of +3.4%. The cumulative pattern—unprofitability, revenue decline, depressed valuation, and repeated insider accumulation amid deteriorating metrics—merits attention to whether this reflects differential information access or simply price-level conviction against broader headwinds.

Director Bolton Jeffrey purchased 7,000 shares of EHAB at blended average $8.38 in two transactions on Aug 8-9, expanding holdings 10.5% to 73,877 shares.

Bolton Jeffrey acquired 7,000 shares across 2 separate purchases totaling $58,650.00, raising his holdings from 66,877 to 73,877 shares. The transactions occurred on 2024-08-08 (2,000 shares at $8.60) and 2024-08-09 (5,000 shares at $8.29), executed just above the current price of $8.17 and near the 52-week low of $7.28. His historical performance at EHAB shows 4 prior trades with timing results: 2 of 3 measurable outcomes showed positive 90-day returns. However, context matters: the company reported negative net income of $-200,000.00 in the latest quarter, annual revenue declined -2.3% year-over-year, and the stock has fallen -40.6% from its 52-week high. The purchase occurs during a 30-day decline of -13.8%, adding to recent momentum loss, and may warrant analysis of whether the director's assessment of fair value diverges from current market sentiment.